In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Our Top 5 Analyst Questions Eli Lilly’s Q1 Earnings Call Asad Haider (Goldman Sachs) asked about the impact of the CVS formulary loss on Zepbound’s market share and future PBM dynamics.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent ...

J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

In the second quarter, J&J’s worldwide oncology sales shot up more than 20 per cent, offsetting declines in sales of its ...

Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...

Johnson & Johnson has slashed on Wednesday its estimate for the impact of tariffs in 2025, which it now expects to be around $200 million. The company’s stock is climbing in morning trading, boosted ...

"Successful second quarter for Camurus" Summary second quarter 2025 April - June Total revenues grew 52% (65% at CER1) to SEK ...

HSBC Global Research has upgraded Divi's Laboratories Ltd. from a ‘reduce’ to a ‘buy’ rating, citing strong growth potential ...